Redhill Biopharma Ltd
NASDAQ:RDHL

Watchlist Manager
Redhill Biopharma Ltd Logo
Redhill Biopharma Ltd
NASDAQ:RDHL
Watchlist
Price: 1.168 USD -3.07% Market Closed
Market Cap: 3.9m USD

Gross Margin
Redhill Biopharma Ltd

60.4%
Current
50%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.4%
=
Gross Profit
7.3m
/
Revenue
12.1m

Gross Margin Across Competitors

No Stocks Found

Redhill Biopharma Ltd
Glance View

Market Cap
3.9m USD
Industry
Pharmaceuticals

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

RDHL Intrinsic Value
9.644 USD
Undervaluation 88%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.4%
=
Gross Profit
7.3m
/
Revenue
12.1m
What is the Gross Margin of Redhill Biopharma Ltd?

Based on Redhill Biopharma Ltd's most recent financial statements, the company has Gross Margin of 60.4%.

Back to Top